Passage Bio (NASDAQ:PASG) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.89) by 11.24 percent. This is a 3.95 percent decrease over losses of $(0.76) per share from the same period last year.
$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.35% on an annualized basis producing an average annual return of 15.26%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.63 billion.
